<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:39:36Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7888373" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7888373</identifier>
        <datestamp>2021-03-25</datestamp>
        <setSpec>gatesmanu</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">N Engl J Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">N Engl J Med</journal-id>
              <journal-id journal-id-type="publisher-id">NEJM</journal-id>
              <journal-title-group>
                <journal-title>The New England Journal of Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0028-4793</issn>
              <issn pub-type="epub">1533-4406</issn>
              <publisher>
                <publisher-name>Massachusetts Medical Society</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7888373</article-id>
              <article-id pub-id-type="pmcid">PMC7888373</article-id>
              <article-id pub-id-type="pmc-uid">7888373</article-id>
              <article-id pub-id-type="pmid">33761206</article-id>
              <article-id pub-id-type="publisher-id">NEJM-2021-2031499</article-id>
              <article-id pub-id-type="doi">10.1056/NEJMoa2031499</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120/MF59 in
Adults</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Gray</surname>
                    <given-names>Glenda E</given-names>
                  </name>
                  <degrees>M.B.B.Ch. F.C.Paed. (S.A.)</degrees>
                  <xref ref-type="aff" rid="aff0001"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bekker</surname>
                    <given-names>Linda-Gail</given-names>
                  </name>
                  <degrees>M.B.Ch.B., F.C.P(S.A.), Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0004"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Laher</surname>
                    <given-names>Fatima</given-names>
                  </name>
                  <degrees>M.B.B.Ch., Dip. HIV Man.(S.A.)</degrees>
                  <xref ref-type="aff" rid="aff0002"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Malahleha</surname>
                    <given-names>Mookho</given-names>
                  </name>
                  <degrees>M.B.Ch.B., Dip. HIV Man.(S.A.), MPH</degrees>
                  <xref ref-type="aff" rid="aff0006"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Allen</surname>
                    <given-names>Mary</given-names>
                  </name>
                  <degrees>R.N., B.S.N., M.S.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Moodie</surname>
                    <given-names>Zoe</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Grunenberg</surname>
                    <given-names>Nicole</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Huang</surname>
                    <given-names>Yunda</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Grove</surname>
                    <given-names>Doug</given-names>
                  </name>
                  <degrees>M.S.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Prigmore</surname>
                    <given-names>Brittany</given-names>
                  </name>
                  <degrees>M.S.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kee</surname>
                    <given-names>Jia J.</given-names>
                  </name>
                  <degrees>M.S.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Benkeser</surname>
                    <given-names>David</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0007"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hural</surname>
                    <given-names>John</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Innes</surname>
                    <given-names>Craig</given-names>
                  </name>
                  <degrees>M.B.Ch.B., M.Sc. Epi</degrees>
                  <xref ref-type="aff" rid="aff0021"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lazarus</surname>
                    <given-names>Erica</given-names>
                  </name>
                  <degrees>M.B.Ch.B.</degrees>
                  <xref ref-type="aff" rid="aff0002"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Meintjes</surname>
                    <given-names>Graeme</given-names>
                  </name>
                  <degrees>M.B.Ch.B. F.C.P.(S.A.), F.R.C.P.(U.K.), M.P.H., Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0010"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Naicker</surname>
                    <given-names>Nivashnee</given-names>
                  </name>
                  <degrees>M.B.Ch.B., M.P.H.</degrees>
                  <xref ref-type="aff" rid="aff0023"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kalonji</surname>
                    <given-names>Dishiki</given-names>
                  </name>
                  <degrees>M.B.B.Ch., F.C.P.H.M.(S.A.), MMed</degrees>
                  <xref ref-type="aff" rid="aff0014"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nchabeleng</surname>
                    <given-names>Maphoshane</given-names>
                  </name>
                  <degrees>M.B.Ch.B., Dip. HIV Man (S.A.), M.Med. Microbiology</degrees>
                  <xref ref-type="aff" rid="aff0008"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sebe</surname>
                    <given-names>Modulakgotla</given-names>
                  </name>
                  <degrees>M.B.Ch.B.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Singh</surname>
                    <given-names>Nishanta</given-names>
                  </name>
                  <degrees>M.B.Ch.B.</degrees>
                  <xref ref-type="aff" rid="aff0014"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kotze</surname>
                    <given-names>Philip</given-names>
                  </name>
                  <degrees>M.B.Ch.B. M.M.E.D.</degrees>
                  <xref ref-type="aff" rid="aff0024"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kassim</surname>
                    <given-names>Sheetal</given-names>
                  </name>
                  <degrees>M.B.Ch.B.</degrees>
                  <xref ref-type="aff" rid="aff0004"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dubula</surname>
                    <given-names>Thozama</given-names>
                  </name>
                  <degrees>M.M.E.D.</degrees>
                  <xref ref-type="aff" rid="aff0009"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Naicker</surname>
                    <given-names>Vimla</given-names>
                  </name>
                  <degrees>M.B.Ch.B. D.A.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brumskine</surname>
                    <given-names>William</given-names>
                  </name>
                  <degrees>M.B.Ch.B., Dip HIV Man (S.A.)</degrees>
                  <xref ref-type="aff" rid="aff0021"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ncayiya</surname>
                    <given-names>Cleon N</given-names>
                  </name>
                  <degrees>B.Sc.</degrees>
                  <xref ref-type="aff" rid="aff0004"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ward</surname>
                    <given-names>Amy M</given-names>
                  </name>
                  <degrees>M.B.B.Ch.</degrees>
                  <xref ref-type="aff" rid="aff0010"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Garrett</surname>
                    <given-names>Nigel</given-names>
                  </name>
                  <degrees>M.B.B.S., Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0023"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kistnasami</surname>
                    <given-names>Girisha</given-names>
                  </name>
                  <degrees>B.Sc.</degrees>
                  <xref ref-type="aff" rid="aff0021"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gaffoor</surname>
                    <given-names>Zakir</given-names>
                  </name>
                  <degrees>M.Sc.</degrees>
                  <xref ref-type="aff" rid="aff0014"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Selepe</surname>
                    <given-names>Pearl</given-names>
                  </name>
                  <degrees>M.B.Ch.B.</degrees>
                  <xref ref-type="aff" rid="aff0021"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Makhoba</surname>
                    <given-names>Philisiwe B</given-names>
                  </name>
                  <degrees>M.B.Ch.B., D.O.H., D.O.A.</degrees>
                  <xref ref-type="aff" rid="aff0024"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mathebula</surname>
                    <given-names>Matsontso P</given-names>
                  </name>
                  <degrees>M.B.Ch.B., M.P.H.</degrees>
                  <xref ref-type="aff" rid="aff0008"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mda</surname>
                    <given-names>Pamela</given-names>
                  </name>
                  <degrees>M.B.Ch.B., M.M.E.D.</degrees>
                  <xref ref-type="aff" rid="aff0009"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Adonis</surname>
                    <given-names>Tania</given-names>
                  </name>
                  <degrees>B Psych</degrees>
                  <xref ref-type="aff" rid="aff0021"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mapetla</surname>
                    <given-names>Katlego S</given-names>
                  </name>
                  <degrees>Btech</degrees>
                  <xref ref-type="aff" rid="aff0006"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Modibedi</surname>
                    <given-names>Bontle</given-names>
                  </name>
                  <degrees>R.N.</degrees>
                  <xref ref-type="aff" rid="aff0002"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Philip</surname>
                    <given-names>Tricia</given-names>
                  </name>
                  <degrees>M.B.Ch.B.</degrees>
                  <xref ref-type="aff" rid="aff0002"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kobane</surname>
                    <given-names>Gladys</given-names>
                  </name>
                  <degrees>Dip Nursing Science</degrees>
                  <xref ref-type="aff" rid="aff0014"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bentley</surname>
                    <given-names>Carter</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ramirez</surname>
                    <given-names>Shelly</given-names>
                  </name>
                  <degrees>MA</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Takuva</surname>
                    <given-names>Simbarashe</given-names>
                  </name>
                  <degrees>M.B.Ch.B., Dip. HIV Man.(S.A.), M.Sc.</degrees>
                  <xref ref-type="aff" rid="aff0002"/>
                  <xref ref-type="aff" rid="aff0003"/>
                  <xref ref-type="aff" rid="aff0011"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jones</surname>
                    <given-names>Megan</given-names>
                  </name>
                  <degrees>R.N. B.S.N. MPH</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sikhosana</surname>
                    <given-names>Mpho</given-names>
                  </name>
                  <degrees>M.B.B.Ch., M.P.H.</degrees>
                  <xref ref-type="aff" rid="aff0021"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Atujuna</surname>
                    <given-names>Millicent</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0004"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Andrasik</surname>
                    <given-names>Michele</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0005"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hejazi</surname>
                    <given-names>Nima S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="aff0022"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Puren</surname>
                    <given-names>Adrian</given-names>
                  </name>
                  <degrees>M.B.B.Ch., Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0020"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wiesner</surname>
                    <given-names>Lubbe</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0013"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Phogat</surname>
                    <given-names>Sanjay</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0016"/>
                  <xref ref-type="aff" rid="aff0017"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Diaz Granados</surname>
                    <given-names>Carlos</given-names>
                  </name>
                  <degrees>M.D., M.Sc.</degrees>
                  <xref ref-type="aff" rid="aff0016"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Koutsoukos</surname>
                    <given-names>Marguerite</given-names>
                  </name>
                  <degrees>M.Sc.</degrees>
                  <xref ref-type="aff" rid="aff0018"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Van Der Meeren</surname>
                    <given-names>Olivier</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff0019"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Barnett</surname>
                    <given-names>Susan W.</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0012"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kanesa-thasan</surname>
                    <given-names>Niranjan</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff0015"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kublin</surname>
                    <given-names>James G.</given-names>
                  </name>
                  <degrees>M.D., M.P.H., M.D.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McElrath</surname>
                    <given-names>M. Juliana</given-names>
                  </name>
                  <degrees>M.D., Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gilbert</surname>
                    <given-names>Peter B.</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Janes</surname>
                    <given-names>Holly</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Corey</surname>
                    <given-names>Lawrence</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                  <xref ref-type="aff" rid="aff0003"/>
                  <on-behalf-of>HVTN 702 Study Team</on-behalf-of>
                </contrib>
                <aff id="aff0001"><label>1</label><bold>GEG:</bold> SAMRC. PHRU, HVTN, Vaccine and Infectious
Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington,
United States of America</aff>
                <aff id="aff0002"><label>2</label><bold>FL, EL, ST, BM, TP:</bold> Perinatal HIV Research Unit,
Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South
Africa</aff>
                <aff id="aff0003"><label>3</label><bold>ZM, HJ, YH, DG, BP, JJK, NG, JGK, MJM, PBG, LC, SR, MJ, ST,
CB, MS, MA, JH:</bold> Vaccine and Infectious Disease Division, Fred
Hutchinson Cancer Research Center, Seattle, Washington, United States of
America</aff>
                <aff id="aff0004"><label>4</label><bold>LGB, SK, MA, CNN:</bold> Desmond Tutu HIV Centre, University
of Cape Town, Cape Town, South Africa</aff>
                <aff id="aff0005"><label>5</label><bold>MA</bold> Vaccine Research Program, Division of AIDS,
National Institute of Allergy and Infectious Diseases, National Institutes of
Health, Bethesda, Maryland, United States of America</aff>
                <aff id="aff0006"><label>6</label><bold>MM, KSM</bold> Setshaba Research Centre, Soshanguve, South
Africa</aff>
                <aff id="aff0007"><label>7</label><bold>DB:</bold> Department of Biostatistics and Bioinformatics,
Rollins School of Public Health, Emory University, Atlanta, Georgia, United
States of America</aff>
                <aff id="aff0008"><label>8</label><bold>MN, MPM:</bold> Mecru Clinical Research Unit (MeCRU), Sefako
Mkgatho Health Sciences University, GaRankuwa, South Africa</aff>
                <aff id="aff0009"><label>9</label><bold>TD, PM:</bold> Nelson Mandela Academic Clinical Research
Unit (NeMACRU) and Department of Internal Medicine and Pharmacology, Walter
Sisulu University, Mthatha, South Africa</aff>
                <aff id="aff0010"><label>10</label><bold>GM, AMW:</bold> Department of Medicine, Wellcome Centre for
Infectious Diseases Research in Africa, and Institute of Infectious Disease and
Molecular Medicine, University of Cape Town, South Africa</aff>
                <aff id="aff0011"><label>11</label><bold>ST:</bold> School of Health Systems and Public Health,
Faculty of Health Sciences, University of Pretoria, South Africa</aff>
                <aff id="aff0012"><label>12</label><bold>SWB:</bold> GSK Vaccines, Cambridge, MA, USA;</aff>
                <aff id="aff0013"><label>13</label><bold>LW:</bold> Division of Clinical Pharmacology, Department of
Medicine, University of Cape Town, Cape Town, South Africa</aff>
                <aff id="aff0014"><label>14</label><bold>NS, DK, GK, ZG:</bold> South African Medical Research
Council, Durban, South Africa</aff>
                <aff id="aff0015"><label>15</label><bold>NKT:</bold> GSK Vaccines, Rockville MD USA</aff>
                <aff id="aff0016"><label>16</label><bold>CDG, SP:</bold> Sanofi Pasteur, Swiftwater, Pennsylvania,
United States of America</aff>
                <aff id="aff0017"><label>17</label><bold>SP:Current affiliation:</bold> GSK, Siena, Italy</aff>
                <aff id="aff0018"><label>18</label><bold>MK:</bold> GSK, Wavre, Belgium</aff>
                <aff id="aff0019"><label>19</label><bold>OVDM:</bold> GSK, Rixensart, Belgium</aff>
                <aff id="aff0020"><label>20</label><bold>AP:</bold> National Institute for Communicable Diseases,
National Health Laboratory Service, Johannesburg, South Africa</aff>
                <aff id="aff0021"><label>21</label><bold>MS, GK, CI, PS, TA, WB:</bold> Aurum Institute, South
Africa</aff>
                <aff id="aff0022"><label>22</label><bold>NSH:</bold> Graduate Group in Biostatistics, University of
California, Berkeley, Center for Computational Biology, University of
California, Berkeley, CA, USA</aff>
                <aff id="aff0023"><label>23</label><bold>NN, NG:</bold> Centre for the AIDS Programme of Research in
South Africa (CAPRISA), University of KwaZulu–Natal, Durban, South
Africa</aff>
                <aff id="aff0024"><label>24</label><bold>PK, PBM:</bold> Qhakaza Mbokodo Research Clinic, Ladysmith,
South Africa</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><bold>Corresponding author contact email</bold>:<email xlink:href="glenda.gray@mrc.ac.za">glenda.gray@mrc.ac.za</email></corresp>
                <fn>
                  <p>This is an Author Final Manuscript, which is the version after external peer
review and before publication in the Journal. The publisher’s version
of record, which includes all New England Journal of Medicine editing and
enhancements, is available at <ext-link ext-link-type="uri" xlink:href="http://www.nejm.org/doi/full/10.1056/NEJMoa2031499">10.1056/NEJMoa2031499</ext-link>.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>25</day>
                <month>3</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>25</day>
                <month>3</month>
                <year>2021</year>
              </pub-date>
              <volume>384</volume>
              <issue>12</issue>
              <fpage>1089</fpage>
              <lpage>1100</lpage>
              <permissions>
                <copyright-statement>Copyright © 2021 Author(s), Massachusetts Medical
Society.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This Author Final Manuscript is licensed for use under the CC BY
license.</license-p>
                </license>
              </permissions>
              <abstract>
                <sec id="s1">
                  <title>BACKGROUND</title>
                  <p>A safe, effective vaccine is essential to end HIV. A canarypox/protein HIV
vaccine regimen showed modest efficacy at reducing infection in Thailand. An
analogous regimen using HIV-1 subtype C virus demonstrated potent humoral
and cellular responses in a Phase 1/2a trial and triggered a Phase 2b/3
double-blinded trial to assess the safety and efficacy of this regimen in
South Africa.</p>
                </sec>
                <sec id="s2">
                  <title>METHODS</title>
                  <p>We enrolled and randomized 5,404 healthy, HIV-uninfected 18-35-year olds at
14 sites to vaccine (2,704 participants) or placebo (2,700 participants)
between 26 October 2016 and 21 June 2019. The vaccine regimen consisted of
two ALVAC-HIV (vCP2438) (expressing HIV-1 subtype C <italic>env,</italic>
clade B <italic>gp41</italic>, <italic>gag</italic> and
<italic>pro)</italic> immunizations at months 0 and 1, with booster
immunizations of ALVAC-HIV plus bivalent subtype C gp120 protein/MF59
adjuvant at months 3, 6, 12 and 18. Efficacy was evaluated by HIV testing
every 3 months.</p>
                </sec>
                <sec id="s3">
                  <title>RESULTS</title>
                  <p>In January 2020, pre-specified non-efficacy criteria were met at an interim
analysis; further vaccinations were subsequently halted. The vaccines were
safe and well-tolerated in the study population (median age 24, 70%
female-sex-at-birth). Over the primary 24-month follow-up, there were 133
infections among placebo recipients and 138 among vaccinees (hazard ratio =
1.02; 95%CI, 0.81-1.30; P=0.84). Pre-specified subgroup analyses
demonstrated no difference in efficacy by sex or when restricting to
follow-up post-4<sup>th</sup> vaccination, and no difference amongst
female-sex-at-birth by age, BMI, prevalent STIs, behavioral risk score or
region.</p>
                </sec>
                <sec id="s4">
                  <title>CONCLUSIONS</title>
                  <p>The ALVAC/gp120 regimen did not prevent HIV infection in South Africans
despite prior evidence of immunogenicity.</p>
                  <p>ClinicalTrials.gov (NCT02968849)</p>
                </sec>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="sec1">
              <title>Introduction</title>
              <p>Most of the 75.7 million people infected with HIV are from sub-Saharan Africa, where
HIV-1 subtype C is prevalent.<sup><xref rid="cit0001" ref-type="bibr">1</xref></sup>
South Africa (SA) bears a disproportionately large HIV burden with approximately 7.9
million persons living with HIV, highlighting the urgent need for a
vaccine.<sup><xref rid="cit0002" ref-type="bibr">2</xref></sup></p>
              <p>In 2010, following the announcement that the RV144 HIV vaccine trial demonstrated 31%
efficacy in a community-based trial in Thailand,<sup><xref rid="cit0003" ref-type="bibr">3</xref></sup> the Pox-Protein Public-Private Partnership (P5)
was established. The P5 developed an analogous regimen using HIV-1 subtype C
sub-Saharan African strains, including a transmitted-founder isolate.<sup><xref rid="cit0004" ref-type="bibr">4</xref></sup> This approach, utilizing a
recombinant canarypox vector containing a subtype C envelope (<italic>env</italic>)
ALVAC-HIV (vCP2438) and MF59-adjuvanted subtype C bivalent gp120 protein vaccine,
was safe and induced strong humoral and cellular immune responses.<sup><xref rid="cit0005" ref-type="bibr">5</xref></sup> We investigated the safety and
efficacy of this vaccine regimen against HIV-1 acquisition in SA.</p>
            </sec>
            <sec sec-type="methods" id="sec2">
              <title>Methods</title>
              <sec id="sec2.1">
                <title>TRIAL DESIGN</title>
                <p>HIV Vaccine Trials Network (HVTN) 702 was a Phase 2b/3 randomized double-blind
placebo-controlled trial of ALVAC-HIV (vCP2438) and MF59-adjuvanted bivalent
subtype C gp120. Participants were randomized 1:1 to vaccine or placebo,
stratified by sex-at-birth and site, with centrally generated randomization by
the Statistical Center for HIV/AIDS Research and Prevention (SCHARP). The trial
was designed to evaluate vaccine efficacy <bold>(</bold>VE) to prevent HIV
infection within 24 months of enrollment (i.e., VE(0-24)) with formal monitoring
for potential harm, non-efficacy, and high efficacy, with potential to extend
follow-up to 36 months.<sup><xref rid="cit0006" ref-type="bibr">6</xref></sup></p>
              </sec>
              <sec id="sec2.2">
                <title>TRIAL POPULATION</title>
                <p>Eligible participants were consenting, healthy, HIV-uninfected 18 to 35-year old
adults at 15 community sites in SA. We aimed to enroll 60-75% persons assigned
female-sex-at-birth (females hereafter). Females of reproductive potential were
required to use contraception until 3 months post-final vaccination;
pregnant/breast-feeding females were excluded.</p>
              </sec>
              <sec id="sec2.3">
                <title>INTERVENTION</title>
                <p>The vaccines were ALVAC-HIV (vCP2438) and MF59-adjuvanted bivalent subtype C
gp120. ALVAC-HIV (vCP2438) (nominal dose of 10⁷ 50% cell culture
infectious dose) expressed the HIV-1 <italic>env</italic> gp120 of the subtype C
ZM96.C strain with the gp41 transmembrane sequence, <italic>gag</italic> and
<italic>protease</italic> from the subtype B LAI strain. Bivalent subtype C
gp120 was a combination of 100 mcg each of the HIV-1 subtype C gp120 of the
TV1.C and 1086.C strains. Placebo was Sodium Chloride for Injection 0.9%,
USP.</p>
                <p>Participants received either ALVAC-HIV at Months 0 and 1 followed by 4
administrations of ALVAC-HIV plus bivalent subtype C gp120/MF59 at Months 3, 6,
12 and 18, or placebo by intramuscular injection. ALVAC-HIV or placebo was
administered in the left deltoid while bivalent subtype C gp120/MF59 or placebo
was administered in the right deltoid.</p>
              </sec>
              <sec id="sec2.4">
                <title>OUTCOME EVALUATION</title>
                <p>Study visits were scheduled at Months 0, 1, 3, 6, 6.5, 12, 12.5, 15, 18, 18.5, 21
and every three months thereafter up to Month 36 with vaccine safety (VE)
evaluated (see Supplementary Materials). Physical examination, HIV risk
reduction counseling, pregnancy assessment, social impact assessment, adverse
event (AE) monitoring and collection of concomitant medications were performed
at every visit. HIV testing with counseling occurred every 3 months, sexually
transmitted infection (STI) testing was done every 6 months and a behavioral
risk questionnaire was performed at screening, months 6.5, 12, 24, and 36.
Access to free pre-exposure prophylaxis and post-exposure prophylaxis (PrEP/PEP)
was provided. Vaccinations were prohibited during pregnancy and
breastfeeding.</p>
              </sec>
              <sec id="sec2.5">
                <title>LABORATORY METHODS</title>
                <p>HIV testing was done at study sites to avoid potential unblinding of treatment.
HIV infection was confirmed by detection of HIV nucleic acid and HIV-1 RNA viral
loads were measured post-diagnosis. An independent adjudication committee
reviewed HIV diagnostic test results from specimens collected on at least two
dates and made the primary determination of infection status and timing. For
monitoring PrEP/PEP use, dried blood spot (DBS) samples were collected on all
participants seen at sites on a given day each month to measure tenofovir
diphosphate (TFV-DP).</p>
              </sec>
              <sec id="sec2.6">
                <title>TRIAL OVERSIGHT</title>
                <p>The trial was designed by investigators, the P5 and collaborators. All data were
collected and analyzed by SCHARP. All authors had access to data and critically
reviewed and approved the manuscript. The first draft was written by the three
lead authors, the statisticians and the senior author. HVTN 702 Study Team is
listed in <bold>Table S1</bold>.</p>
              </sec>
              <sec id="sec2.7">
                <title>ETHICAL CONSIDERATIONS</title>
                <p>All participants provided written informed consent in their preferred language
before screening. The research ethics committees of the Universities of the
Witwatersrand, Cape Town, KwaZulu-Natal, Sefako Makgatho University and the
South African Medical Research Council approved the trial. The trial was
overseen by the NIAID HIV Vaccine Data and Safety Monitoring Board (DSMB) and
registered with the South African National Clinical Trials Register (SANCTR
number: DOH-27-0916-5327) and ClinicalTrials.gov (NCT02968849).</p>
              </sec>
              <sec id="sec2.8">
                <title>STATISTICAL ANALYSIS</title>
                <p>The primary efficacy outcome, VE(0-24), was measured as 1 minus the hazard ratio
for HIV-1 infection, estimated using a sex-stratified Cox proportional-hazards
model and tested using a sex-stratified log-rank test. VE was also measured
using a ratio of cumulative incidences of HIV-1 infection, vaccine vs. placebo,
and estimated using transformed Nelson-Aalen cumulative hazard functions.
Secondary analyses evaluated VE from Month 6.5 to 24 (VE(6.5-24)), starting two
weeks post-4<sup>th</sup> vaccination, and VE from Month 0 to 36 (VE(0-36)).
Follow-up time was the number of days from randomization to HIV-1 diagnosis; or
for participants without HIV-1 infection diagnosis, from randomization to the
last HIV-1 negative test or to the end of the Month 24 (or Month 36) visit
window, whichever occurred first. Kaplan-Meier plots show the cumulative
incidence of time to HIV-1 infection and loss-to-follow-up. Pre-specified
baseline variables were evaluated as modifiers of VE by Wald interaction tests,
using stratified Cox proportional hazards models with Holm<sup><xref rid="cit0007" ref-type="bibr">7</xref></sup> multiplicity
adjustment.</p>
                <p>The primary efficacy analysis was based on the modified intention-to-treat (MITT)
cohort, defined as all enrolled participants, apart from those diagnosed with
HIV-1 infection on the day of enrollment, and analyzed according to the
randomized treatment. Secondary efficacy analyses evaluated the Month 6.5
at-risk cohort (MITT participants on-study and HIV-1-negative at Month 6.5, at
risk of subsequent HIV-1 infection) and the per-protocol (PP) cohort, defined as
participants in the Month 6.5 at-risk cohort who received the first four
vaccinations on schedule without error. Safety analyses included all randomized
participants who received at least one injection and analyzed according to the
treatment received.</p>
                <p>The sample size of 5,400 participants provided at least 90% power to reject a
null hypothesis of VE(0-24) ≤ 25% if the true VE was 50% or more, based
on an assumed 4% placebo group annual HIV-1 incidence (<bold>Tables
S2-S3</bold>).</p>
                <p>Continuous monitoring for a potential vaccine-induced increased HIV risk began at
12 infections until non-efficacy monitoring commenced at 59 infections,
occurring approximately every 6 months through 24 months follow-up of
participants. The pre-specified non-efficacy stopping criteria were that the
lower limits of 95% confidence intervals (CIs) for both VE(0-24) and VE(6.5-24)
lay below 0% and upper limits lay below 40%, for both Cox proportional hazards
and cumulative incidence ratio estimation approaches; and that at least 60% of
enrolled participants had reached the Month 18.5 visit.</p>
                <p>The data presented are on visits and evaluations through February 18, 2020, prior
to study unblinding on February 19, 2020.</p>
                <p>All P values are two-sided, with P values &lt;0.05 considered statistically
significant. Further details are provided in Supplementary Materials.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec3">
              <title>Results</title>
              <sec id="sec3.1">
                <title>Study population</title>
                <p>Between 26 October 2016 and 21 June 2019, 9,919 individuals were screened and
5,407 enrolled (<xref ref-type="fig" rid="f0001"><bold>Fig. 1</bold></xref>). Of
these, three participants were enrolled twice and only data from the first
enrollment were used. Of the 5,404 unique participants enrolled, 2,704 were
randomized to vaccine and 2,700 to placebo. Baseline demographic, clinical and
HIV-1 risk factors were similar between treatment groups (<xref rid="t0001" ref-type="table"><bold>Table 1</bold></xref>). Overall, 3,786 (70%) participants
were female, with 1,115 (29%) aged 18-21 years. Participants assigned
male-at-birth (hereafter, male) tended to be older, with 859 (53%) at least 26
years. At enrollment, 1,194/3,389 (35%) females and 264/1,254 (21%) males were
diagnosed with STIs. Detailed baseline participant characteristics are in
<bold>Tables S4-S9</bold>.</p>
                <fig id="f0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <p><bold>Screening, randomization, enrollment, and study outcomes.</bold><sup>¥</sup>Top 3 reasons for ineligibility shown.
<sup>*</sup>4 participants were screened and found ineligible
but sex-at-birth not recorded. <sup>+</sup>3 participants were
randomized and enrolled twice and only data from the first randomization
and enrollment is considered. <sup>§</sup>Participant is not in
Month 6.5 at-risk cohort because no HIV diagnostic test was performed
after Month 6.5 and prior to study unblinding. <sup>‡</sup>Other
product administration errors include incorrect site of administration,
product expired, and other.</p>
                  </caption>
                  <graphic xlink:href="NEJM-2021-2031499-g001"/>
                </fig>
                <table-wrap id="t0001" orientation="portrait" position="float">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline characteristics of enrolled participants, by sex-at-birth and
treatment assignment.</p>
                  </caption>
                  <table frame="border" rules="all">
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1"/>
                        <th colspan="3" align="center" rowspan="1">Females, n (%)</th>
                        <th colspan="3" align="center" rowspan="1">Males, n (%)</th>
                      </tr>
                      <tr>
                        <th align="left" rowspan="1" colspan="1"/>
                        <th align="center" rowspan="1" colspan="1">Total n=3786</th>
                        <th align="center" rowspan="1" colspan="1">lacebo n=1893</th>
                        <th align="center" rowspan="1" colspan="1">Vaccine n=1893</th>
                        <th align="center" rowspan="1" colspan="1">Total n=1618</th>
                        <th align="center" rowspan="1" colspan="1">Placebo n=807</th>
                        <th align="center" rowspan="1" colspan="1">Vaccine n=811</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td colspan="7" align="left" rowspan="1">
                          <bold>Age (years)</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 18-21</td>
                        <td align="center" rowspan="1" colspan="1">1115 (29)</td>
                        <td align="center" rowspan="1" colspan="1">572 (30)</td>
                        <td align="center" rowspan="1" colspan="1">543 (29)</td>
                        <td align="center" rowspan="1" colspan="1">321 (20)</td>
                        <td align="center" rowspan="1" colspan="1">155 (19)</td>
                        <td align="center" rowspan="1" colspan="1">166 (20)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 22-25</td>
                        <td align="center" rowspan="1" colspan="1">1420 (38)</td>
                        <td align="center" rowspan="1" colspan="1">697 (37)</td>
                        <td align="center" rowspan="1" colspan="1">723 (38)</td>
                        <td align="center" rowspan="1" colspan="1">438 (27)</td>
                        <td align="center" rowspan="1" colspan="1">219 (27)</td>
                        <td align="center" rowspan="1" colspan="1">219 (27)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 26-35</td>
                        <td align="center" rowspan="1" colspan="1">1251 (33)</td>
                        <td align="center" rowspan="1" colspan="1">624 (33)</td>
                        <td align="center" rowspan="1" colspan="1">627 (33)</td>
                        <td align="center" rowspan="1" colspan="1">859 (53)</td>
                        <td align="center" rowspan="1" colspan="1">433 (54)</td>
                        <td align="center" rowspan="1" colspan="1">426 (53)</td>
                      </tr>
                      <tr>
                        <td colspan="7" align="left" rowspan="1">
                          <bold>BMI</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> &lt;18.5</td>
                        <td align="center" rowspan="1" colspan="1">133 (4)</td>
                        <td align="center" rowspan="1" colspan="1">77 (4)</td>
                        <td align="center" rowspan="1" colspan="1">56 (3)</td>
                        <td align="center" rowspan="1" colspan="1">232 (14)</td>
                        <td align="center" rowspan="1" colspan="1">118 (15)</td>
                        <td align="center" rowspan="1" colspan="1">114 (14)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 18.5-24</td>
                        <td align="center" rowspan="1" colspan="1">1406 (37)</td>
                        <td align="center" rowspan="1" colspan="1">681 (36)</td>
                        <td align="center" rowspan="1" colspan="1">725 (38)</td>
                        <td align="center" rowspan="1" colspan="1">1127 (70)</td>
                        <td align="center" rowspan="1" colspan="1">567 (70)</td>
                        <td align="center" rowspan="1" colspan="1">560 (69)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 25-29</td>
                        <td align="center" rowspan="1" colspan="1">978 (26)</td>
                        <td align="center" rowspan="1" colspan="1">485 (26)</td>
                        <td align="center" rowspan="1" colspan="1">493 (26)</td>
                        <td align="center" rowspan="1" colspan="1">194 (12)</td>
                        <td align="center" rowspan="1" colspan="1">97 (12)</td>
                        <td align="center" rowspan="1" colspan="1">97 (12)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> ≥30</td>
                        <td align="center" rowspan="1" colspan="1">1269 (34)</td>
                        <td align="center" rowspan="1" colspan="1">650 (34)</td>
                        <td align="center" rowspan="1" colspan="1">619 (33)</td>
                        <td align="center" rowspan="1" colspan="1">65 (4)</td>
                        <td align="center" rowspan="1" colspan="1">25 (3)</td>
                        <td align="center" rowspan="1" colspan="1">40 (5)</td>
                      </tr>
                      <tr>
                        <td colspan="7" align="left" rowspan="1">
                          <bold>Gender identity</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Female</td>
                        <td align="center" rowspan="1" colspan="1">3783 (100)</td>
                        <td align="center" rowspan="1" colspan="1">1891 (100)</td>
                        <td align="center" rowspan="1" colspan="1">1892 (100)</td>
                        <td align="center" rowspan="1" colspan="1">6 (0)</td>
                        <td align="center" rowspan="1" colspan="1">1 (0)</td>
                        <td align="center" rowspan="1" colspan="1">5 (1)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Male</td>
                        <td align="center" rowspan="1" colspan="1">2 (0)</td>
                        <td align="center" rowspan="1" colspan="1">1 (0)</td>
                        <td align="center" rowspan="1" colspan="1">1 (0)</td>
                        <td align="center" rowspan="1" colspan="1">1598 (99)</td>
                        <td align="center" rowspan="1" colspan="1">797 (99)</td>
                        <td align="center" rowspan="1" colspan="1">801 (99)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Transgender female/male</td>
                        <td align="center" rowspan="1" colspan="1">1 (0)</td>
                        <td align="center" rowspan="1" colspan="1">1 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">10 (1)</td>
                        <td align="center" rowspan="1" colspan="1">6 (1)</td>
                        <td align="center" rowspan="1" colspan="1">4 (0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Gender variant</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">2 (0)</td>
                        <td align="center" rowspan="1" colspan="1">1 (0)</td>
                        <td align="center" rowspan="1" colspan="1">1 (0)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Prefer not to answer</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                        <td align="center" rowspan="1" colspan="1">2 (0)</td>
                        <td align="center" rowspan="1" colspan="1">2 (0)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td colspan="7" align="left" rowspan="1">
                          <bold>Condom use (in
general)</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Always</td>
                        <td align="center" rowspan="1" colspan="1">209 (6)</td>
                        <td align="center" rowspan="1" colspan="1">121 (6)</td>
                        <td align="center" rowspan="1" colspan="1">88 (5)</td>
                        <td align="center" rowspan="1" colspan="1">140 (9)</td>
                        <td align="center" rowspan="1" colspan="1">61 (8)</td>
                        <td align="center" rowspan="1" colspan="1">79 (10)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Sometimes</td>
                        <td align="center" rowspan="1" colspan="1">2790 (74)</td>
                        <td align="center" rowspan="1" colspan="1">1379 (73)</td>
                        <td align="center" rowspan="1" colspan="1">1411 (75)</td>
                        <td align="center" rowspan="1" colspan="1">1228 (76)</td>
                        <td align="center" rowspan="1" colspan="1">627 (78)</td>
                        <td align="center" rowspan="1" colspan="1">601 (74)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Never</td>
                        <td align="center" rowspan="1" colspan="1">786 (21)</td>
                        <td align="center" rowspan="1" colspan="1">393 (21)</td>
                        <td align="center" rowspan="1" colspan="1">393 (21)</td>
                        <td align="center" rowspan="1" colspan="1">249 (15)</td>
                        <td align="center" rowspan="1" colspan="1">119 (15)</td>
                        <td align="center" rowspan="1" colspan="1">130 (16)</td>
                      </tr>
                      <tr>
                        <td colspan="7" align="left" rowspan="1">
                          <bold>Exchange of sex for
money/gifts<xref ref-type="table-fn" rid="tf1-1">*</xref></bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Yes</td>
                        <td align="center" rowspan="1" colspan="1">791 (21)</td>
                        <td align="center" rowspan="1" colspan="1">407 (22)</td>
                        <td align="center" rowspan="1" colspan="1">384 (20)</td>
                        <td align="center" rowspan="1" colspan="1">256 (16)</td>
                        <td align="center" rowspan="1" colspan="1">128 (16)</td>
                        <td align="center" rowspan="1" colspan="1">128 (16)</td>
                      </tr>
                      <tr>
                        <td colspan="7" align="left" rowspan="1">
                          <bold>Number of sex acts<xref ref-type="table-fn" rid="tf1-1">*</xref></bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 0-4</td>
                        <td align="center" rowspan="1" colspan="1">1238 (33)</td>
                        <td align="center" rowspan="1" colspan="1">614 (32)</td>
                        <td align="center" rowspan="1" colspan="1">624 (33)</td>
                        <td align="center" rowspan="1" colspan="1">455 (28)</td>
                        <td align="center" rowspan="1" colspan="1">226 (28)</td>
                        <td align="center" rowspan="1" colspan="1">229 (28)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> 5-10</td>
                        <td align="center" rowspan="1" colspan="1">1373 (36)</td>
                        <td align="center" rowspan="1" colspan="1">671 (35)</td>
                        <td align="center" rowspan="1" colspan="1">702 (37)</td>
                        <td align="center" rowspan="1" colspan="1">609 (38)</td>
                        <td align="center" rowspan="1" colspan="1">299 (37)</td>
                        <td align="center" rowspan="1" colspan="1">310 (38)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> ≥11</td>
                        <td align="center" rowspan="1" colspan="1">1173 (31)</td>
                        <td align="center" rowspan="1" colspan="1">606 (32)</td>
                        <td align="center" rowspan="1" colspan="1">567 (30)</td>
                        <td align="center" rowspan="1" colspan="1">554 (34)</td>
                        <td align="center" rowspan="1" colspan="1">282 (35)</td>
                        <td align="center" rowspan="1" colspan="1">272 (34)</td>
                      </tr>
                      <tr>
                        <td colspan="7" align="left" rowspan="1">
                          <bold>Lives with spouse/main
partner</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Yes</td>
                        <td align="center" rowspan="1" colspan="1">530 (14)</td>
                        <td align="center" rowspan="1" colspan="1">291 (15)</td>
                        <td align="center" rowspan="1" colspan="1">239 (13)</td>
                        <td align="center" rowspan="1" colspan="1">278 (17)</td>
                        <td align="center" rowspan="1" colspan="1">134 (17)</td>
                        <td align="center" rowspan="1" colspan="1">144 (18)</td>
                      </tr>
                      <tr>
                        <td colspan="7" align="left" rowspan="1">
                          <bold>Sexually transmitted
infections<xref ref-type="table-fn" rid="tf1-2">$</xref></bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Syphilis</td>
                        <td align="center" rowspan="1" colspan="1">44 (1)</td>
                        <td align="center" rowspan="1" colspan="1">23 (1)</td>
                        <td align="center" rowspan="1" colspan="1">21 (1)</td>
                        <td align="center" rowspan="1" colspan="1">26 (2)</td>
                        <td align="center" rowspan="1" colspan="1">16 (3)</td>
                        <td align="center" rowspan="1" colspan="1">10 (2)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Neisseria gonorrhoeae</td>
                        <td align="center" rowspan="1" colspan="1">179 (5)</td>
                        <td align="center" rowspan="1" colspan="1">89 (5)</td>
                        <td align="center" rowspan="1" colspan="1">90 (5)</td>
                        <td align="center" rowspan="1" colspan="1">39 (3)</td>
                        <td align="center" rowspan="1" colspan="1">20 (3)</td>
                        <td align="center" rowspan="1" colspan="1">19 (3)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Chlamydia trachomatis</td>
                        <td align="center" rowspan="1" colspan="1">779 (23)</td>
                        <td align="center" rowspan="1" colspan="1">371 (22)</td>
                        <td align="center" rowspan="1" colspan="1">408 (24)</td>
                        <td align="center" rowspan="1" colspan="1">199 (16)</td>
                        <td align="center" rowspan="1" colspan="1">96 (16)</td>
                        <td align="center" rowspan="1" colspan="1">103 (16)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"> Trichomonas vaginalis</td>
                        <td align="center" rowspan="1" colspan="1">192 (6)</td>
                        <td align="center" rowspan="1" colspan="1">95 (6)</td>
                        <td align="center" rowspan="1" colspan="1">97 (6)</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tf1-1">
                      <label>*</label>
                      <p>Timeframe for question is the previous 30 days.</p>
                    </fn>
                    <fn id="tf1-2">
                      <label>$</label>
                      <p>STI testing was introduced in version 2 of the protocol and so data
is not available on 763 participants (397 females and 366 males).
Percentages are computed relative to the numbers tested.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>The MITT cohort included 5,384 participants (2,689 placebo and 2,695 vaccine)
followed for a median of 623 days (interquartile range [IQR]: 427, 819). Month
6.5 at-risk cohort median follow-up was 642 days (IQR: 459, 756) and 644 days in
the PP cohort (IQR: 461, 756). Loss-to-follow-up was low (3.9/100 person-years
for vaccine group; 3.9/100 person-years for placebo group; <bold>Fig S1</bold>).
Protocol adherence was high (<bold>Tables S10, S11</bold>).</p>
              </sec>
              <sec id="sec3.2">
                <title>Efficacy</title>
                <sec id="s3b1">
                  <title>HIV-1 infection</title>
                  <p>During the first 24 months of follow-up, 138 HIV-1 infections accrued in the
vaccine group and 133 in the placebo group of the MITT cohort, yielding
estimated incidence rates of 3.4/100 person-years (95% CI: 2.8 to 4.0) and
3.3/100 person-years (95% CI: 2.8 to 3.9), respectively (<xref ref-type="fig" rid="f0002"><bold>Figure 2A</bold></xref>). The primary
efficacy outcome, estimated vaccine vs. placebo hazard ratio (HR), was 1.02
(95% CI: 0.81, 1.30) (<xref rid="t0002" ref-type="table"><bold>Table
2</bold></xref>). No differences in HIV incidence between vaccine
and placebo groups were seen in secondary analyses over the full 36 months
of follow-up (HR=1.05, 95% CI: 0.83 to 1.31), in the Month 6.5 at-risk
cohort (HR =1.15, 95% CI: 0.84 to 1.58) (<xref rid="t0002" ref-type="table"><bold>Table 2</bold></xref>), or in additional secondary VE
analyses, including PP VE (<bold>Figures S2-S8</bold>). No differential VE
was evident over Months 0-24 by sex-at-birth (interaction P=0.92); estimated
HR=1.03 among females (95% CI: 0.80 to 1.33) and 0.99 among males (95% CI:
0.50 to 1.98) (<xref rid="t0002" ref-type="table"><bold>Table
2</bold></xref>
<bold>and</bold>
<xref ref-type="fig" rid="f0003"><bold>Figure 3A</bold></xref>). HIV
incidence among females was 4.3/100 person-years (95% CI: 3.6 to 5.2) in the
vaccine group and 4.2/100 person-years (95% CI: 3.5 to 5.0) in the placebo
group, whereas among males the incidence was 1.3/100 person-years (95% CI:
0.7 to 2.0) amongst vaccine vs. 1.3/100 person-years (95% CI: 0.7 to 2.1)
amongst placebo recipients (<xref ref-type="fig" rid="f0003"><bold>Figure
3A</bold></xref>). Secondary analyses also included pre-specified
assessment of potential vaccine effect modification by age, baseline HIV
risk score, body mass index (BMI) and region over Months 0-24 among females.
None of these factors were found to modify VE (multiplicity-adjusted
interaction P values ≥0.09; <bold>Table S12</bold>).</p>
                  <fig id="f0002" orientation="portrait" position="float">
                    <label>Figure 2</label>
                    <caption>
                      <p><bold>Cumulative incidence of HIV-1 infection.</bold> A. MITT cohort,
0-24 months. B. Month 6.5 at-risk cohort, 6.5-24 months. C. MITT
cohort, 0-36 months. Inset shows the same data on an expanded
axis.</p>
                    </caption>
                    <graphic xlink:href="NEJM-2021-2031499-g002"/>
                  </fig>
                  <fig id="f0003" orientation="portrait" position="float">
                    <label>Figure 3</label>
                    <caption>
                      <p><bold>Cumulative incidence of HIV-1 infection by pre-specified
baseline variables.</bold> Cumulative incidence over months 0-24
in the MITT cohort, by sex-at-birth (A) and by age among females
(B). Inset shows the same data on an expanded axis.</p>
                    </caption>
                    <graphic xlink:href="NEJM-2021-2031499-g003"/>
                  </fig>
                  <table-wrap id="t0002" orientation="portrait" position="float">
                    <label>Table 2</label>
                    <caption>
                      <p><bold>Rate of HIV-1 infection and estimated hazard ratio for HIV-1
infection (Vaccine vs. Placebo)</bold>. Data are shown for the
Modified Intention-to-Treat (MITT) and the Month 6.5 At-Risk
(M6.5AR) cohorts overall, by sex-at-birth and by follow-up period,
and by age among females.</p>
                    </caption>
                    <table frame="border" rules="all">
                      <thead>
                        <tr>
                          <th align="left" rowspan="1" colspan="1"/>
                          <th colspan="4" align="center" rowspan="1">Vaccine (n =2695)</th>
                          <th colspan="4" align="center" rowspan="1">Placebo (n = 2689)</th>
                          <th align="center" rowspan="1" colspan="1">Method<xref ref-type="table-fn" rid="tf2-2"><sup>+</sup></xref></th>
                          <th align="center" rowspan="1" colspan="1">Estimate</th>
                        </tr>
                        <tr>
                          <th align="left" rowspan="1" colspan="1">Cohort (time period)</th>
                          <th align="center" rowspan="1" colspan="1">No. evaluated</th>
                          <th align="center" rowspan="1" colspan="1">No. infect.</th>
                          <th align="center" rowspan="1" colspan="1">No. of person-yrs.</th>
                          <th align="center" rowspan="1" colspan="1">Rate no./pyrs. (%)</th>
                          <th align="center" rowspan="1" colspan="1">No. evaluated</th>
                          <th align="center" rowspan="1" colspan="1">No. infect.</th>
                          <th align="center" rowspan="1" colspan="1">No. of person-yrs.</th>
                          <th align="center" rowspan="1" colspan="1">Rate no./pyrs. (%)</th>
                          <th align="center" rowspan="1" colspan="1"/>
                          <th align="center" rowspan="1" colspan="1">HR (95% CI)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">MITT cohort (Month 0-24)</td>
                          <td align="center" rowspan="1" colspan="1">2695</td>
                          <td align="center" rowspan="1" colspan="1">138</td>
                          <td align="center" rowspan="1" colspan="1">4098.3</td>
                          <td align="center" rowspan="1" colspan="1">0.034</td>
                          <td align="center" rowspan="1" colspan="1">2689</td>
                          <td align="center" rowspan="1" colspan="1">133</td>
                          <td align="center" rowspan="1" colspan="1">4052.7</td>
                          <td align="center" rowspan="1" colspan="1">0.033</td>
                          <td align="center" rowspan="1" colspan="1">Cox</td>
                          <td align="center" rowspan="1" colspan="1">1.02 (0.81, 1.30)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">MITT cohort (Month 0-24)</td>
                          <td align="center" rowspan="1" colspan="1">2695</td>
                          <td align="center" rowspan="1" colspan="1">138</td>
                          <td align="center" rowspan="1" colspan="1">4098.3</td>
                          <td align="center" rowspan="1" colspan="1">0.034</td>
                          <td align="center" rowspan="1" colspan="1">2689</td>
                          <td align="center" rowspan="1" colspan="1">133</td>
                          <td align="center" rowspan="1" colspan="1">4052.7</td>
                          <td align="center" rowspan="1" colspan="1">0.033</td>
                          <td align="center" rowspan="1" colspan="1">CIR</td>
                          <td align="center" rowspan="1" colspan="1">1.03 (0.81, 1.31)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">MITT cohort (Month 0-36)</td>
                          <td align="center" rowspan="1" colspan="1">2695</td>
                          <td align="center" rowspan="1" colspan="1">151</td>
                          <td align="center" rowspan="1" colspan="1">4477.9</td>
                          <td align="center" rowspan="1" colspan="1">0.034</td>
                          <td align="center" rowspan="1" colspan="1">2689</td>
                          <td align="center" rowspan="1" colspan="1">143</td>
                          <td align="center" rowspan="1" colspan="1">4438.7</td>
                          <td align="center" rowspan="1" colspan="1">0.032</td>
                          <td align="center" rowspan="1" colspan="1">Cox</td>
                          <td align="center" rowspan="1" colspan="1">1.05 (0.83, 1.31)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">MITT cohort (Month 0-30<xref ref-type="table-fn" rid="tf2-3">*</xref>)</td>
                          <td align="center" rowspan="1" colspan="1">2695</td>
                          <td align="center" rowspan="1" colspan="1">147</td>
                          <td align="center" rowspan="1" colspan="1">4392.6</td>
                          <td align="center" rowspan="1" colspan="1">0.036</td>
                          <td align="center" rowspan="1" colspan="1">2689</td>
                          <td align="center" rowspan="1" colspan="1">141</td>
                          <td align="center" rowspan="1" colspan="1">4350.0</td>
                          <td align="center" rowspan="1" colspan="1">0.032</td>
                          <td align="center" rowspan="1" colspan="1">CIR</td>
                          <td align="center" rowspan="1" colspan="1">1.05 (0.81, 1.36)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">M6.5AR cohort<xref ref-type="table-fn" rid="tf2-1"><sup>ǂ</sup></xref> (Month
6.5-24)</td>
                          <td align="center" rowspan="1" colspan="1">2430</td>
                          <td align="center" rowspan="1" colspan="1">83</td>
                          <td align="center" rowspan="1" colspan="1">2804.0</td>
                          <td align="center" rowspan="1" colspan="1">0.030</td>
                          <td align="center" rowspan="1" colspan="1">2393</td>
                          <td align="center" rowspan="1" colspan="1">71</td>
                          <td align="center" rowspan="1" colspan="1">2760.6</td>
                          <td align="center" rowspan="1" colspan="1">0.026</td>
                          <td align="center" rowspan="1" colspan="1">Cox</td>
                          <td align="center" rowspan="1" colspan="1">1.15 (0.84, 1.58)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">M6.5AR cohort<xref ref-type="table-fn" rid="tf2-1"><sup>ǂ</sup></xref> (Month
6.5-24)</td>
                          <td align="center" rowspan="1" colspan="1">2430</td>
                          <td align="center" rowspan="1" colspan="1">83</td>
                          <td align="center" rowspan="1" colspan="1">2804.0</td>
                          <td align="center" rowspan="1" colspan="1">0.030</td>
                          <td align="center" rowspan="1" colspan="1">2393</td>
                          <td align="center" rowspan="1" colspan="1">71</td>
                          <td align="center" rowspan="1" colspan="1">2760.6</td>
                          <td align="center" rowspan="1" colspan="1">0.026</td>
                          <td align="center" rowspan="1" colspan="1">CIR</td>
                          <td align="center" rowspan="1" colspan="1">1.12 (0.81, 1.54)</td>
                        </tr>
                        <tr>
                          <td colspan="11" align="left" rowspan="1">Sex at birth, MITT cohort (Month
0-24)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Female</td>
                          <td align="center" rowspan="1" colspan="1">1887</td>
                          <td align="center" rowspan="1" colspan="1">122</td>
                          <td align="center" rowspan="1" colspan="1">2819.9</td>
                          <td align="center" rowspan="1" colspan="1">0.043</td>
                          <td align="center" rowspan="1" colspan="1">1886</td>
                          <td align="center" rowspan="1" colspan="1">117</td>
                          <td align="center" rowspan="1" colspan="1">2787.3</td>
                          <td align="center" rowspan="1" colspan="1">0.042</td>
                          <td align="center" rowspan="1" colspan="1">Cox</td>
                          <td align="center" rowspan="1" colspan="1">1.03 (0.80, 1.33)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Male</td>
                          <td align="center" rowspan="1" colspan="1">808</td>
                          <td align="center" rowspan="1" colspan="1">16</td>
                          <td align="center" rowspan="1" colspan="1">1278.4</td>
                          <td align="center" rowspan="1" colspan="1">0.013</td>
                          <td align="center" rowspan="1" colspan="1">803</td>
                          <td align="center" rowspan="1" colspan="1">16</td>
                          <td align="center" rowspan="1" colspan="1">1265.5</td>
                          <td align="center" rowspan="1" colspan="1">0.013</td>
                          <td align="center" rowspan="1" colspan="1">Cox</td>
                          <td align="center" rowspan="1" colspan="1">0.99 (0.50, 1.98)</td>
                        </tr>
                        <tr>
                          <td colspan="11" align="left" rowspan="1">Age, Female MITT cohort (Month
0-24 )</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">≤ 25 years</td>
                          <td align="center" rowspan="1" colspan="1">1264</td>
                          <td align="center" rowspan="1" colspan="1">87</td>
                          <td align="center" rowspan="1" colspan="1">1832.1</td>
                          <td align="center" rowspan="1" colspan="1">0.047</td>
                          <td align="center" rowspan="1" colspan="1">1267</td>
                          <td align="center" rowspan="1" colspan="1">80</td>
                          <td align="center" rowspan="1" colspan="1">1829.6</td>
                          <td align="center" rowspan="1" colspan="1">0.044</td>
                          <td align="center" rowspan="1" colspan="1">Cox</td>
                          <td align="center" rowspan="1" colspan="1">1.08 (0.80, 1.47)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">&gt; 25 years</td>
                          <td align="center" rowspan="1" colspan="1">623</td>
                          <td align="center" rowspan="1" colspan="1">35</td>
                          <td align="center" rowspan="1" colspan="1">987.8</td>
                          <td align="center" rowspan="1" colspan="1">0.035</td>
                          <td align="center" rowspan="1" colspan="1">619</td>
                          <td align="center" rowspan="1" colspan="1">37</td>
                          <td align="center" rowspan="1" colspan="1">957.7</td>
                          <td align="center" rowspan="1" colspan="1">0.039</td>
                          <td align="center" rowspan="1" colspan="1">Cox</td>
                          <td align="center" rowspan="1" colspan="1">0.92 (0.58, 1.46)</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <fn id="tf2-1">
                        <label>ǂ</label>
                        <p>The Month 6.5 at-risk (M6.5AR) cohort is the set of modified
intent-to-treat (MITT) participants on-study and HIV-1-negative
at Month 6.5, at-risk of subsequent HIV-1 infection.</p>
                      </fn>
                      <fn id="tf2-2">
                        <label>+</label>
                        <p>Hazard ratio (HR) (Vaccine vs. Placebo) is estimated using the
Cox proportional hazards model or using the Cumulative Incidence
Ratio (CIR).</p>
                      </fn>
                      <fn id="tf2-3">
                        <label>*</label>
                        <p>Cumulative Incidence Ratio is estimated over the time period
where there are at least 150 participants of either sex-at-birth
at risk.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec id="s3b2">
                  <title>Post-infection viral load</title>
                  <p>Among the 294 MITT participants diagnosed with HIV-1 infection over the full
36 months of follow-up (<bold>Table S13</bold>), mean log10 viral loads at
the time of diagnosis were similar between vaccine and placebo recipients
(4.82 log<sub>10</sub> copies/mL, 95% CI: 4.61 to 5.02 and 4.64
log<sub>10</sub> copies/mL, 95% CI: 4.45 to 4.84; <bold>Figure
S9</bold>). The median time to antiretroviral therapy initiation was 13
weeks in the vaccine vs. 14 weeks in the placebo group (P = 0.5, log-rank
test; <bold>Figure S10</bold>).</p>
                </sec>
                <sec id="s3b3">
                  <title>PrEP/PEP use</title>
                  <p>Despite PrEP being freely available, overall PrEP/PEP use was low: 120 (3.2%)
females and 52 (3.2%) males self-reporting PrEP use and 91 (2.4%) females
and 80 (4.9%) males self-reporting PEP use at any time (<bold>Table
S14</bold>). Of the 2,405 DBS samples collected, TFV-DP levels were
detectable in 51 (2.12%), reaching effective levels in five (<bold>Tables
S15, S16</bold>). Overall, an estimated 2.89% person-years had
detectable PrEP/PEP in the placebo and 1.99% in the vaccine group.</p>
                </sec>
                <sec id="s3b4">
                  <title>Safety, reactogenicity and death</title>
                  <p>Product administration errors were rare: 3 of 2704 participants randomized to
vaccine and 2 of 2700 participants randomized to placebo received incorrect
product. Participants receiving vaccine at any visit were analyzed as
vaccinees for safety analyses. Vaccinations were safe and well-tolerated
(<bold>Tables S17-S19</bold>). Vaccine recipients were more likely than
placebo recipients to report reactogenicity (46.2% vs. 32.8%,
P&lt;0.001), with pain and/or tenderness most frequently reported for
vaccine (23.0%) and headache reported most frequently by placebo recipients
(15.7%). Most symptoms were mild. AEs were well-balanced between groups
(<bold>Table S20</bold>) with AEs “related” to study
product uncommon but more frequent in vaccine recipients (1.4% vs. 0.4% of
placebo recipients, P&lt;0.001). The few related AEs resulting in
vaccination discontinuation included generalized rash (2 placebo, 1
vaccine), generalized urticaria (1 vaccine), cellulitis (1 vaccine),
diarrhea (1 placebo), and headache (1 placebo).</p>
                </sec>
                <sec id="s3b5">
                  <title>Deaths</title>
                  <p>Eighteen deaths, all judged unrelated, were reported in 10 placebo and 8
vaccine recipients (Supplementary Materials).</p>
                </sec>
                <sec id="s3b6">
                  <title>Pregnancies</title>
                  <p>Only 163 pregnancies were reported (82 in vaccine, 81 in placebo recipients),
yielding a 2.65% annual pregnancy rate. For 78 (48%) pregnancies, oral
hormonal contraception was the method last reported. No congenital anomalies
were reported.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="discussion" id="sec4">
              <title>Discussion</title>
              <p>We found no effect of the vaccine on HIV-1 acquisition in this well-powered study.
The trial met the pre-specified non-efficacy stopping criteria in an interim
analysis in January 2020 with no safety concerns. The DSMB recommended that
vaccinations be stopped, participants unblinded and followed for one year post-last
vaccination.</p>
              <p>HVTN 702 differed from RV144 in inserts (ZM96 vs. 92TH023; 1086 and TV1 vs. A244,
MN), adjuvants (MF59 vs. alum), and an additional boost (Month 18).<sup><xref rid="cit0008" ref-type="bibr">8</xref>-<xref rid="cit0010" ref-type="bibr">10</xref></sup> Differing patterns of immunogenicity were seen in studies
comparing the two regimens in SA. HVTN 100 evaluated immunogenicity of the HVTN 702
regimen and was compared to HVTN 097, a study that evaluated the RV144 regimen in
SA.<sup><xref rid="cit0011" ref-type="bibr">11</xref></sup> Binding and
functional antibodies to gp120/gp140 antigens and T-cell responses to
vaccine-matched peptide pools were of greater magnitude in HVTN 100, while the V2
region antibody responses, which were important correlates of risk in
RV144,<sup><xref rid="cit0012" ref-type="bibr">12</xref></sup> were higher
for the RV144 regimen as assessed in both RV144 and HVTN 097.<sup><xref rid="cit0013" ref-type="bibr">13</xref></sup> The substantial differences in
antibody specificities induced by vaccination in these two regimens suggest that
viral sequences or adjuvants may influence the elicitation of V2-specific
antibodies, identified as a correlate of decreased HIV-1 risk.<sup><xref rid="cit0014" ref-type="bibr">14</xref></sup></p>
              <p>HIV-1 acquisition, and potentially HIV-1 exposure, was markedly higher in our study
compared to RV144. Genital tract inflammation was likely prevalent, given the high
STI prevalence among women.<sup><xref rid="cit0015" ref-type="bibr">15</xref></sup>
The 4.2% HIV-1 incidence in HVTN 702 females was 14 times higher than seen in RV144
females (0.30%). This incidence reflects hyperendemic HIV transmission in the
community, likely from high frequency of acute infections and low rates of viral
suppression.<sup><xref rid="cit0016" ref-type="bibr">16</xref></sup> In
RV144, lower VE was observed among participants at high risk of HIV-1 acquisition
compared to those at low/moderate risk.<sup><xref rid="cit0017" ref-type="bibr">17</xref></sup> In nonhuman primates vaccinated with ALVAC gp120, better
protection from experimental mucosal infection was achieved with low-dose compared
to high-dose challenge,<sup><xref rid="cit0018" ref-type="bibr">18</xref></sup>
providing a possible explanation about the role that “force” of
infection plays in overcoming vaccine-induced immunity. We did not find efficacy in
any subgroup, even those determined low risk for HIV-1 acquisition based on STI and
behavioral data, however the eligibility criteria and burden of HIV in SA would
suggest that few “low risk” women were enrolled.</p>
              <p>The significantly greater genetic diversity of the sub-Saharan African subtype C
epidemic compared to that of the AE epidemic in Thailand 15 years ago when RV144 was
conducted is also likely to have played a role in the differential efficacy between
the trials. VE in RV144 was found to depend on viral genetics, especially the match
of exposing HIV-1 to vaccine insert at Env position 169 in the V2 loop.<sup><xref rid="cit0019" ref-type="bibr">19</xref></sup> Studies suggest that the
frequency of 169-match to the HVTN 702 vaccine is much less common in SA vs.
Thailand,<sup><xref rid="cit0020" ref-type="bibr">20</xref></sup> as is
match of the V1V2 region of the HVTN 702 vaccine components with circulating SA
sequences compared to their RV144 Thailand counterparts based on HIV sequence data
from the Los Alamos National Labs (LANL) database<sup><xref rid="cit0021" ref-type="bibr">21</xref></sup> (Supplementary Materials, <bold>Figure
S11</bold>).</p>
              <p>Host genetic factors that may influence VE also differ between the South African and
Thai populations. RV144 data suggest that VE depends on <italic>FCGR2C</italic> and
HLA-A*02 genotype.<sup><xref rid="cit0022" ref-type="bibr">22</xref>-<xref rid="cit0024" ref-type="bibr">24</xref></sup> Recent data suggest SA has
relatively low prevalence of FCR and HLA class I genotypes associated with high VE
in RV144<sup><xref rid="cit0025" ref-type="bibr">25</xref>-<xref rid="cit0027" ref-type="bibr">27</xref></sup> (Supplementary Materials, <bold>Table
S21</bold>).</p>
              <p>Limitations to our study include the inability to directly compare the RV144 and HVTN
702 regimens within the same study to address differences in the vector, adjuvants,
and proteins. The absence of an available immunological biomarker to predict
protection further compounds our ability to infer whether differences in efficacy
are explained by observed differences in immunogenicity or by other factors such as
infection force and viral diversity. Additional studies on the immunology and viral
sequences are underway to improve our understanding of the results and implications
for the field.</p>
              <p>Given the many differences between the HVTN 702 and RV144 studies — between
the vaccines and the immune responses they generated; the differences in the level
of viral exposure; the extent of matching between the vaccines and the exposing
viruses; and in host genetics and other host factors − isolating which factor
or combination of factors is responsible for the different efficacy results will be
challenging.</p>
            </sec>
            <sec sec-type="conclusion" id="sec5">
              <title>Conclusion</title>
              <p>Despite promising immunogenicity, this canarypox/protein prime/boost HIV vaccine
regimen was not efficacious. The high HIV-1 incidence observed in this study
illustrates an unrelenting epidemic, especially amongst young women. More than ever,
a vaccine to prevent HIV-1 acquisition is needed.</p>
            </sec>
            <sec id="sec6">
              <title>Disclosure</title>
              <p>Disclosure forms provided by the authors are available with the full text of this
article at NEJM.org.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="S1">
                <media xlink:href="NEJM-2021-2031499-s1.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>The authors wish to thank the trial participants and staff, the study teams,
community members, the HVTN Core staff, the Hutchinson Centre Research Institute of
South Africa (HCRISA) staff, the Statistical Center for HIV/AIDS Research &amp;
Prevention (SCHARP), the HVTN Laboratory Center, the DAIDS/NIAID Vaccine Research
Program, and the Pharmaceutical Affairs Branch, Triclinium Clinical Development, and
the P5 partners including Sanofi Pasteur, GSK, Bill &amp; Melinda Gates
Foundation, the National Institute of Allergy and Infectious Diseases (NIAID), the
National Institutes of Health (NIH), the United States Military HIV Research
Program, and the South African Medical Research Council. We thank Nina Russell and
Margaret Johnston from the Bill and Melinda Gates Foundation for their wise counsel.
We also are in gratitude to Michael Pensiero from NIH/NIAID for oversight on product
development. We thank Jacqueline Odhiambo for her ongoing project management support
and Ashley Clayton and Mindy Miner for assistance with manuscript development and
technical editing. In loving memory of our Regional Medical Liaison, Dr Keitumetse
Diphoko.</p>
              <p>The content is solely the responsibility of the authors and does not necessarily
represent the official views of the National Institute of Allergy and Infectious
Diseases (NIAID), the National Institutes of Health (NIH), or the Gates Foundation.
GlaxoSmithKline Biologicals SA was provided the opportunity to review a preliminary
version of this manuscript for factual accuracy, but the authors are solely
responsible for final content and interpretation.</p>
            </ack>
            <sec>
              <title>Funding</title>
              <p>Funding was provided to Novartis Vaccines and Diagnostics (now part of the
GlaxoSmithKline Biologicals SA) by NIAID (HHSN272201300033C//HHSN272201600012C) for
the selection and process development of the two gp120 envelope proteins TV1.C and
1086.C, and by the Bill &amp; Melinda Gates Foundation Global Health Grant
OPP1017604 and NIAID for the manufacture and release of the gp120 clinical grade
material. GlaxoSmithKline Biologicals SA has contributed financially to PrEP
provision. Funding was also provided by NIAID U.S. Public Health Service Grants UM1
AI068614 [LOC: HIV Vaccine Trials Network], UM1 AI068635 [HVTN SDMC FHCRC], and UM1
AI068618 [HVTN Laboratory Center FHCRC]. The South African Medical Research Council
supported SAMRC affiliated research sites.</p>
            </sec>
            <sec>
              <title>Conflicts of interest</title>
              <p>MKO, OVDM and SP are employed by and hold shares in the GSK group of companies. LW no
conflict of interest</p>
            </sec>
            <ref-list id="references">
              <title>References</title>
              <ref id="cit0001">
                <label>1</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>UNAIDS</collab></person-group>. <source>UNAIDS Fact Sheet
2018</source>. <publisher-loc>Geneva, Switzerland</publisher-loc><year>2018</year>.</mixed-citation>
              </ref>
              <ref id="cit0002">
                <label>2</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Human Sciences Research Council</collab></person-group>.
<source>The Fifth South African National HIV Prevalence, Incidence,
Behaviour and Communication Survey, 2017: HIV Impact Assessment Summary
Report</source>. <publisher-loc>Cape Town, South Africa</publisher-loc><year>2018</year>.</mixed-citation>
              </ref>
              <ref id="cit0003">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rerks-Ngarm</surname><given-names>S</given-names></string-name>,
<string-name><surname>Pitisuttithum</surname><given-names>P</given-names></string-name>,
<string-name><surname>Nitayaphan</surname><given-names>S</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>Vaccination with ALVAC and AIDSVAX
to prevent HIV-1 infection in Thailand</article-title>. <source>N Engl J
Med</source><year>2009</year>;<volume>361</volume>:<fpage>2209</fpage>-<lpage>20</lpage>.<pub-id pub-id-type="pmid">19843557</pub-id></mixed-citation>
              </ref>
              <ref id="cit0004">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gray</surname><given-names>G</given-names></string-name>,
<string-name><surname>Doherty</surname><given-names>T</given-names></string-name>,
<string-name><surname>Mohapi</surname><given-names>L</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>HIV research in South Africa:
Advancing life</article-title>. <source>South African Medical
Journal</source><year>2019</year>;<volume>109</volume>:<fpage>36</fpage>-<lpage>40</lpage>.<pub-id pub-id-type="pmid">32252866</pub-id></mixed-citation>
              </ref>
              <ref id="cit0005">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Laher</surname><given-names>F</given-names></string-name>,
<string-name><surname>Moodie</surname><given-names>Z</given-names></string-name>,
<string-name><surname>Cohen</surname><given-names>KW</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>Safety and immune responses after a
12-month booster in healthy HIV-uninfected adults in HVTN 100 in South
Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV
(vCP2438) and bivalent subtype C gp120/MF59 vaccines</article-title>.
<source>PLoS Med</source><year>2020</year>;<volume>17</volume>:<fpage>e1003038</fpage>.<pub-id pub-id-type="pmid">32092060</pub-id></mixed-citation>
              </ref>
              <ref id="cit0006">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gilbert</surname><given-names>PB</given-names></string-name>,
<string-name><surname>Grove</surname><given-names>D</given-names></string-name>,
<string-name><surname>Gabriel</surname><given-names>E</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>A Sequential Phase 2b Trial Design
for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV
Vaccine Regimens</article-title>. <source>Stat Commun Infect Dis</source><year>2011</year>;<volume>3</volume>.</mixed-citation>
              </ref>
              <ref id="cit0007">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Holm</surname><given-names>S</given-names></string-name></person-group>.
<article-title>A Simple Sequentially Rejective Multiple Test
Procedure</article-title>. <source>Scandinavian Journal of
Statistics</source><year>1979</year>;<volume>6</volume>:<fpage>65</fpage>-<lpage>70</lpage>.</mixed-citation>
              </ref>
              <ref id="cit0008">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O'Hagan</surname><given-names>DT</given-names></string-name></person-group>.
<article-title>MF59 is a safe and potent vaccine adjuvant that enhances
protection against influenza virus infection</article-title>. <source>Expert
Rev Vaccines</source><year>2007</year>;<volume>6</volume>:<fpage>699</fpage>-<lpage>710</lpage>.<pub-id pub-id-type="pmid">17931151</pub-id></mixed-citation>
              </ref>
              <ref id="cit0009">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>O'Hagan</surname><given-names>DT</given-names></string-name>,
<string-name><surname>Ott</surname><given-names>GS</given-names></string-name>, <string-name><surname>De
Gregorio</surname><given-names>E</given-names></string-name>,
<string-name><surname>Seubert</surname><given-names>A</given-names></string-name></person-group>.
<article-title>The mechanism of action of MF59 - an innately attractive
adjuvant formulation</article-title>. <source>Vaccine</source><year>2012</year>;<volume>30</volume>:<fpage>4341</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="pmid">22682289</pub-id></mixed-citation>
              </ref>
              <ref id="cit0010">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shen</surname><given-names>X</given-names></string-name>,
<string-name><surname>Laher</surname><given-names>F</given-names></string-name>,
<string-name><surname>Moodie</surname><given-names>Z</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>HIV-1 Vaccine Sequences Impact V1V2
Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine
Regimens</article-title>. <source>Sci Rep</source><year>2020</year>;<volume>10</volume>:<fpage>2093</fpage>.<pub-id pub-id-type="pmid">32034163</pub-id></mixed-citation>
              </ref>
              <ref id="cit0011">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bekker</surname><given-names>LG</given-names></string-name>,
<string-name><surname>Moodie</surname><given-names>Z</given-names></string-name>,
<string-name><surname>Grunenberg</surname><given-names>N</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>Subtype C ALVAC-HIV and bivalent
subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South
African adults: a phase 1/2 trial</article-title>. <source>Lancet
HIV</source><year>2018</year>;<volume>5</volume>:<fpage>e366</fpage>-<lpage>e78</lpage>.<pub-id pub-id-type="pmid">29898870</pub-id></mixed-citation>
              </ref>
              <ref id="cit0012">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gottardo</surname><given-names>R</given-names></string-name>,
<string-name><surname>Bailer</surname><given-names>RT</given-names></string-name>,
<string-name><surname>Korber</surname><given-names>BT</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>Plasma IgG to linear epitopes in
the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of
infection in the RV144 vaccine efficacy trial</article-title>. <source>PLoS
One</source><year>2013</year>;<volume>8</volume>:<fpage>e75665</fpage>.<pub-id pub-id-type="pmid">24086607</pub-id></mixed-citation>
              </ref>
              <ref id="cit0013">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gray</surname><given-names>GE</given-names></string-name>,
<string-name><surname>Huang</surname><given-names>Y</given-names></string-name>,
<string-name><surname>Grunenberg</surname><given-names>N</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>Immune correlates of the Thai RV144
HIV vaccine regimen in South Africa</article-title>. <source>Sci Transl
Med</source><year>2019</year>;<volume>11</volume>.</mixed-citation>
              </ref>
              <ref id="cit0014">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Haynes</surname><given-names>BF</given-names></string-name>,
<string-name><surname>Gilbert</surname><given-names>PB</given-names></string-name>,
<string-name><surname>McElrath</surname><given-names>MJ</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>Immune-correlates analysis of an
HIV-1 vaccine efficacy trial</article-title>. <source>N Engl J Med</source><year>2012</year>;<volume>366</volume>:<fpage>1275</fpage>-<lpage>86</lpage>.<pub-id pub-id-type="pmid">22475592</pub-id></mixed-citation>
              </ref>
              <ref id="cit0015">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Passmore</surname><given-names>JA</given-names></string-name>,
<string-name><surname>Jaspan</surname><given-names>HB</given-names></string-name>,
<string-name><surname>Masson</surname><given-names>L</given-names></string-name></person-group>.
<article-title>Genital inflammation, immune activation and risk of sexual
HIV acquisition</article-title>. <source>Curr Opin HIV AIDS</source><year>2016</year>;<volume>11</volume>:<fpage>156</fpage>-<lpage>62</lpage>.<pub-id pub-id-type="pmid">26628324</pub-id></mixed-citation>
              </ref>
              <ref id="cit0016">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Powers</surname><given-names>KA</given-names></string-name>,
<string-name><surname>Ghani</surname><given-names>AC</given-names></string-name>,
<string-name><surname>Miller</surname><given-names>WC</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>The role of acute and early HIV
infection in the spread of HIV and implications for transmission prevention
strategies in Lilongwe, Malawi: a modelling study</article-title>.
<source>Lancet</source><year>2011</year>;<volume>378</volume>:<fpage>256</fpage>-<lpage>68</lpage>.<pub-id pub-id-type="pmid">21684591</pub-id></mixed-citation>
              </ref>
              <ref id="cit0017">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robb</surname><given-names>ML</given-names></string-name>,
<string-name><surname>Rerks-Ngarm</surname><given-names>S</given-names></string-name>,
<string-name><surname>Nitayaphan</surname><given-names>S</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>Risk behaviour and time as
covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and
AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV
144</article-title>. <source>Lancet Infect Dis</source><year>2012</year>;<volume>12</volume>:<fpage>531</fpage>-<lpage>7</lpage>.<pub-id pub-id-type="pmid">22652344</pub-id></mixed-citation>
              </ref>
              <ref id="cit0018">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vaccari</surname><given-names>M</given-names></string-name>,
<string-name><surname>Keele</surname><given-names>BF</given-names></string-name>,
<string-name><surname>Bosinger</surname><given-names>SE</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>Protection afforded by an HIV
vaccine candidate in macaques depends on the dose of SIVmac251 at challenge
exposure</article-title>. <source>J Virol</source><year>2013</year>;<volume>87</volume>:<fpage>3538</fpage>-<lpage>48</lpage>.<pub-id pub-id-type="pmid">23325681</pub-id></mixed-citation>
              </ref>
              <ref id="cit0019">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rolland</surname><given-names>M</given-names></string-name>,
<string-name><surname>Edlefsen</surname><given-names>PT</given-names></string-name>,
<string-name><surname>Larsen</surname><given-names>BB</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>Increased HIV-1 vaccine efficacy
against viruses with genetic signatures in Env V2</article-title>.
<source>Nature</source><year>2012</year>;<volume>490</volume>:<fpage>417</fpage>-<lpage>20</lpage>.<pub-id pub-id-type="pmid">22960785</pub-id></mixed-citation>
              </ref>
              <ref id="cit0020">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rademeyer</surname><given-names>C</given-names></string-name>,
<string-name><surname>Korber</surname><given-names>B</given-names></string-name>,
<string-name><surname>Seaman</surname><given-names>MS</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>Features of Recently Transmitted
HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for
Active and Passive Immunization</article-title>. <source>PLoS
Pathog</source><year>2016</year>;<volume>12</volume>:<fpage>e1005742</fpage>.<pub-id pub-id-type="pmid">27434311</pub-id></mixed-citation>
              </ref>
              <ref id="cit0021">
                <label>21</label>
                <mixed-citation publication-type="web"><person-group person-group-type="author"><collab>Los Alamos National Labs</collab></person-group>
(<comment>Accessed September 28, 2020, at <ext-link ext-link-type="uri" xlink:href="http://www.hiv.lanl.gov/">http://www.hiv.lanl.gov/</ext-link>.</comment>)</mixed-citation>
              </ref>
              <ref id="cit0022">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>SS</given-names></string-name>,
<string-name><surname>Gilbert</surname><given-names>PB</given-names></string-name>,
<string-name><surname>Tomaras</surname><given-names>GD</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>FCGR2C polymorphisms associate with
HIV-1 vaccine protection in RV144 trial</article-title>. <source>J Clin
Invest</source><year>2014</year>;<volume>124</volume>:<fpage>3879</fpage>-<lpage>90</lpage>.<pub-id pub-id-type="pmid">25105367</pub-id></mixed-citation>
              </ref>
              <ref id="cit0023">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gartland</surname><given-names>AJ</given-names></string-name>,
<string-name><surname>Li</surname><given-names>S</given-names></string-name>,
<string-name><surname>McNevin</surname><given-names>J</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>Analysis of HLA A*02
association with vaccine efficacy in the RV144 HIV-1 vaccine
trial</article-title>. <source>J Virol</source><year>2014</year>;<volume>88</volume>:<fpage>8242</fpage>-<lpage>55</lpage>.<pub-id pub-id-type="pmid">24829343</pub-id></mixed-citation>
              </ref>
              <ref id="cit0024">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Prentice</surname><given-names>HA</given-names></string-name>,
<string-name><surname>Tomaras</surname><given-names>GD</given-names></string-name>,
<string-name><surname>Geraghty</surname><given-names>DE</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>HLA class II genes modulate
vaccineinduced antibody responses to affect HIV-1
acquisition</article-title>. <source>Sci Transl Med</source><year>2015</year>;<volume>7</volume>:<fpage>296ra112</fpage>.</mixed-citation>
              </ref>
              <ref id="cit0025">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lassauniere</surname><given-names>R</given-names></string-name>,
<string-name><surname>Tiemessen</surname><given-names>CT</given-names></string-name></person-group>.
<article-title>Variability at the FCGR locus: characterization in Black
South Africans and evidence for ethnic variation in and out of
Africa</article-title>. <source>Genes Immun</source><year>2016</year>;<volume>17</volume>:<fpage>93</fpage><lpage>104</lpage>.<pub-id pub-id-type="pmid">26673965</pub-id></mixed-citation>
              </ref>
              <ref id="cit0026">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hertz</surname><given-names>T</given-names></string-name>,
<string-name><surname>Logan</surname><given-names>MG</given-names></string-name>,
<string-name><surname>Rolland</surname><given-names>M</given-names></string-name>, <etal>et
al</etal></person-group>. <article-title>A study of vaccine-induced immune
pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine
efficacy trial</article-title>. <source>Vaccine</source><year>2016</year>;<volume>34</volume>:<fpage>5792</fpage>-<lpage>801</lpage>.<pub-id pub-id-type="pmid">27756485</pub-id></mixed-citation>
              </ref>
              <ref id="cit0027">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tshabalala</surname><given-names>M</given-names></string-name>,
<string-name><surname>Mellet</surname><given-names>J</given-names></string-name>,
<string-name><surname>Pepper</surname><given-names>MS</given-names></string-name></person-group>.
<article-title>Human Leukocyte Antigen Diversity: A Southern African
Perspective</article-title>. <source>J Immunol Res</source><year>2015</year>;<volume>2015</volume>:<fpage>746151</fpage>.<pub-id pub-id-type="pmid">26347896</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
